title: [Candidate patient for treatment with continuous apomorphine infusion].
abstract: Subcutaneous apomorphine infusion has been shown to be effective in reducing motor fluctuations and, to a lesser extent, also the levodopa induced dyskinesias in patients with advanced Parkinson's disease (PD). Based on the literature data, the following article reviews the clinical features of PD patients in order to be considered candidates for this therapy. In general, the vast majority of patients with advanced PD can benefit from this therapy and the authors' experience suggests that it should be considered as soon as the conventional pharmacological therapy fails to significantly reduce the number of daily off hours.
authors.affiliation: Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Espana.
authors.forename: María José
authors.initials: MJ
authors.lastname: Martí
authors.forename: Jaume
authors.initials: J
authors.lastname: Kulisevsky
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001058:Apomorphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000150:complications; D000075202:Contraindications; D003863:Depression / Q000150:complications; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006212:Hallucinations / Q000139:chemically induced / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D018579:Patient Selection; D011605:Psychoses, Substance-Induced / Q000209:etiology; D011618:Psychotic Disorders / Q000150:complications
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D001058:Apomorphine